NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: modifying budgets in portugal one item from slovenia) |
(Changed label, description and/or aliases in fr: Adding French translations) |
||
| label / fr | label / fr | ||
NEUROTERA: Pour la mise sur le marché de nouveaux agents thérapeutiques contre les comorbidités oculaires et cérébrales associées à la paramylose | |||
Revision as of 19:22, 5 December 2021
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,221.0 Euro
0 references
1,136,308.0 Euro
0 references
78.43 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references